Tagged with M

ANAFAM This is your 3rd interview with Focus Reports. What would you say has been the biggest change that has shaped the pharmaceutical industry since we last interviewed you in 2008? The main change in the last 4 years has been the close relationship that we’ve established with the authorities. Before…

Zambon You declared in a recent interview that Zambon Group will always keep complying with the vision of your father Alberto, who has always refused acquisition offers from multinationals- a striking approach, in a context of pharmaceutical clusters when so many Italian players have been swallowed by wider structures. Which specific…

CROM You are specialised in Cardiology at Padua University, in Tropical Medicine and Hygiene at London University and in Pharmacology at Modena University, in Communication at Bocconi University in Milan, and also have 12 years of experience in all aspects of drug development in a major international pharmaceutical company. What aspect…

CANIFARMA This is your third interview with Focus Reports. In 2004 and 2008 you were Director of AMIIF, before that you were Director of ANAFAM, and now we’re delighted to be interviewing you as General Director of CANIFARMA with over 30 years of experience in the industry. There have been a…

Menarini After 67 years in the pharmaceutical industry, of which 45 at the head of Menarini, what would you say have been your personal keys to success? Most of my life, I worked three shifts. Meaning arriving at the office at 8:30am, come back home at 1pm, back to work at…

ADM Korea How did you first get involved in clinical trials and what inspired you to create your own CRO, ADM Korea? When I was working at CJ, the company was starting to produce bimolecular products, specifically they were working on vaccines. CJ needed personnel with expertise in this area and I…

Bristol-Myers Squibb The pharmaceutical industry in Asia is undergoing a period of specialization with R&D booming in places like Australia, Singapore and South Korea and manufacturing in places like China, India and now Vietnam – how does Indonesia fit into the overall picture? Indonesia has a number of very strong fundamental, macroeconomic…

Nordic Pharma France Nordic Pharma has been established in the French market since 2002 as one of its first steps towards internationalization. What have been the main milestones and achievements of Nordic in the French market since then? Since our establishment on the French market in 2002, Nordic Pharma has had a number…

Minister of Higher Education and Research What has been the contribution of the LRU reform and specifically what has the Creation of Research Centers and Higher Education (PRES) done to establish universities back at the heart of the research strategy in France? French research produces excellent results, but still suffers from a lack of international visibility,…

Tecnoquímicas S.A.  Mr. Sardi, Exec-VP of Tecnoquímicas, the No. 1 producer and distributor of generic pharmaceutical drugs in Colombia, explains what makes Tecnoquímicas different from their contemporaries and how it grew with the changing landscape of the Colombian market to regain their No. 1 spot. What have been the constant factors that…

Endotis Pharma Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from near scratch in 2003 based on a specific project that was unsuccessful at the time but rejuvenated in 2005 with…

Cegedim Deutschland GmbH You joined Cegedim in summer 2006 eleven months before its merger with Dendrite in 2007 that created the world leader in pharmaceutical CRM. How would you describe the integration process of both companies and what were the main synergies between Cegedim and Dendrite in the German context? Germany offered a…